Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Significant Drop in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant drop in short interest during the month of April. As of April 30th, there was short interest totaling 413,675 shares, a drop of 55.4% from the April 15th total of 926,778 shares. Currently, 6.6% of the shares of the company are sold short. Based on an average trading volume of 1,653,442 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Avalon GloboCare Stock Performance

ALBT stock traded down $0.00 during mid-day trading on Friday, hitting $0.34. The company had a trading volume of 6,092 shares, compared to its average volume of 4,959,861. Avalon GloboCare has a 12 month low of $0.21 and a 12 month high of $4.74. The stock’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $1.00. The firm has a market cap of $2.85 million, a PE ratio of -0.10 and a beta of -0.04.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.49) earnings per share (EPS) for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.